Antengene targets HK$2.8bn from Hong Kong IPO

Jonathan Breen

November 09, 2020 06:45 am

Healthcare medical biopharmaceutical investing stock chart background | Kurhan - stock.adobe.com

Antengene Corp, a clinical stage biopharmaceutical company, has set its Hong Kong listing in motion. It has opened bookbuilding for an up to HK$2.79bn ($359.4m) IPO.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

JP Morgan Equity IPOs Health and Biotech Equity China Merchants Bank Co China China International Capital Corp Citi Hong Kong SAR Asia Greater China Northeast Asia Asia Pacific Emerging Markets SRI Goldman Sachs

JB

Jonathan Breen

Equities editor GlobalCapital Asia